Centurylink Investment Management Company Lowered Phillips 66 (PSX) Holding; 4 Bullish Analysts Covering Anthera Pharmaceuticals, Inc. (ANTH)

Phillips 66 (NYSE:PSX) Logo

Centurylink Investment Management Company decreased Phillips 66 (PSX) stake by 17.39% reported in 2017Q4 SEC filing. Centurylink Investment Management Company sold 3,981 shares as Phillips 66 (PSX)’s stock declined 5.13%. The Centurylink Investment Management Company holds 18,909 shares with $1.91 million value, down from 22,890 last quarter. Phillips 66 now has $50.78B valuation. The stock increased 0.95% or $1.03 during the last trading session, reaching $108.89. About 2.49 million shares traded or 8.34% up from the average. Phillips 66 (NYSE:PSX) has risen 23.90% since April 19, 2017 and is uptrending. It has outperformed by 12.35% the S&P500.

Among 7 analysts covering Anthera Pharmaceuticals (NASDAQ:ANTH), 4 have Buy rating, 1 Sell and 2 Hold. Therefore 57% are positive. Anthera Pharmaceuticals has $15 highest and $1.35 lowest target. $6.83’s average target is 1962.82% above currents $0.3311 stock price. Anthera Pharmaceuticals had 21 analyst reports since August 13, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, September 17 by Citigroup. The rating was reinitiated by Jefferies with “Buy” on Friday, February 19. As per Thursday, December 29, the company rating was maintained by H.C. Wainwright. Piper Jaffray maintained it with “Overweight” rating and $1.35 target in Thursday, December 29 report. The firm earned “Hold” rating on Thursday, December 29 by Jefferies. The rating was downgraded by Citigroup to “Neutral” on Thursday, December 29. Jefferies maintained Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) rating on Tuesday, March 6. Jefferies has “Hold” rating and $2.0 target. Jefferies maintained Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) on Monday, June 26 with “Hold” rating. As per Tuesday, September 12, the company rating was maintained by Jefferies. Jefferies maintained the shares of ANTH in report on Sunday, August 6 with “Hold” rating. See Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) latest ratings:

12/03/2018 Broker: Piper Jaffray Rating: Sell Downgrade
06/03/2018 Broker: Jefferies Rating: Hold New Target: $2.0 Maintain
21/02/2018 Broker: Roth Capital Rating: Buy New Target: $10 Initiates Coverage On
13/02/2018 Broker: Jefferies Rating: Hold New Target: $1.75 Maintain
22/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $4.0 Maintain
15/11/2017 Broker: Jefferies Rating: Hold New Target: $2.0 Maintain

The stock decreased 0.15% or $0.0005 during the last trading session, reaching $0.3311. About 264,559 shares traded. Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has declined 90.50% since April 19, 2017 and is downtrending. It has underperformed by 102.05% the S&P500.

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. The company has market cap of $7.75 million. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of immunoglobulin A nephropathy. It currently has negative earnings.

Analysts await Phillips 66 (NYSE:PSX) to report earnings on April, 27 before the open. They expect $0.84 earnings per share, up 50.00% or $0.28 from last year’s $0.56 per share. PSX’s profit will be $391.71 million for 32.41 P/E if the $0.84 EPS becomes a reality. After $1.07 actual earnings per share reported by Phillips 66 for the previous quarter, Wall Street now forecasts -21.50% negative EPS growth.

Among 19 analysts covering Phillips 66 (NYSE:PSX), 8 have Buy rating, 2 Sell and 9 Hold. Therefore 42% are positive. Phillips 66 has $137.0 highest and $63 lowest target. $98.75’s average target is -9.31% below currents $108.89 stock price. Phillips 66 had 76 analyst reports since August 4, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Friday, September 30 by Goldman Sachs. The firm has “Sector Perform” rating given on Monday, November 2 by RBC Capital Markets. As per Monday, October 16, the company rating was downgraded by Jefferies. The firm has “Buy” rating given on Thursday, September 28 by Scotia Capital. On Monday, September 4 the stock rating was maintained by Jefferies with “Hold”. The rating was downgraded by Goldman Sachs on Monday, November 23 to “Sell”. Oppenheimer maintained Phillips 66 (NYSE:PSX) rating on Friday, September 18. Oppenheimer has “Outperform” rating and $95 target. As per Tuesday, August 1, the company rating was maintained by RBC Capital Markets. The stock has “Equal-Weight” rating by Barclays Capital on Wednesday, July 13. Credit Suisse downgraded it to “Neutral” rating and $105 target in Monday, November 2 report.

Phillips 66 (NYSE:PSX) Institutional Positions Chart